1/2
Today I completed my second Plasma Adsorption session at Edogawa Hospital in Tokyo under Dr. Kato.
@shonyan đŻđ«¶đđŻđ”
I want to explain exactly what this treatment is, why it is the most targeted blood filtration available for vax and long COVID injury, and why the options currently available in the United States. While helpful for some, these do not reach the same depth of selective removal and cannot produce the same results.
Here is how it works. My blood is drawn out through a catheter in my neck. The plasma is separated from my blood cells and run through a column called the IMMUSORBA TR-350, made by Asahi Kasei Medical in Japan. Inside that column, the pathological antibodies and immune complexes circulating in my blood bind directly to the column material and are captured. My own cleaned plasma is then returned to my body. No donor fluids. No foreign proteins. Just my own blood cleaned and returned.
This is not new. This device has been used in Japan since the 1980s with published clinical studies dating to 1984. It is an approved medical device used to treat myasthenia gravis, Guillain-BarrĂ© syndrome, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, and NMDA receptor antibody encephalitis. Every single one of those conditions is driven by the same mechanism destroying vax and long COVID patients â pathological antibodies and immune complexes attacking the nervous system and vascular system. Now here is how it compares to what is available elsewhere.
TPE â Therapeutic Plasma Exchang is the closest option available in US hospitals. Your plasma is removed and thrown away, then replaced with albumin solution or donor fresh frozen plasma. The problem is it removes everything indiscriminately â the bad and the good. Your own clotting factors, your beneficial proteins, your healthy antibodies all go out with the pathological ones. It also requires large volumes of donor substitution fluid which carries infection risk and protein allergy risk.
DFPP â Double Filtration Plasmapheresis â is widely used in Japan and Asia and is now being offered in Europe for long COVID and vax injury patients under the name INUSpheresis. It uses two filters and is more selective than TPE. It returns your own purified plasma to you and requires minimal substitution fluid. However the manufacturer's own documentation states it is still semi-selective, meaning some beneficial components of similar molecular size to the pathogens may also be lost in the process. INUSpheresis is not yet available as standard clinical practice in the United States, though one clinic is currently participating in an early clinical trial toward FDA approval.
H.E.L.P. Apheresis â Heparin-induced Extracorporeal LDL Precipitation â is available in Germany and Cyprus and has been proposed for long COVID. Here is how it works. Blood cells are separated from plasma, heparin is added, and the pH is lowered using an acetate buffer. This causes LDL cholesterol, lipoprotein(a), and fibrinogen to precipitate out and be captured in a filter. The excess heparin is removed, pH is normalized, and the cleaned plasma is returned. It reduces LDL, Lp(a), and fibrinogen by approximately 50-60% per session and has shown benefit for improving microcirculation and dissolving forming microthrombi. It is not available in the United States. The important distinction from PA is that H.E.L.P. works by chemical precipitation and primarily targets lipoproteins and fibrinogen. PA works by molecular affinity bonding and specifically targets pathological antibodies and immune complexes. They are removing different things through completely different mechanisms. For vax injury driven by pathological antibodies and immune complexes, PA is the more directly targeted tool.